[go: up one dir, main page]

WO2005104871A1 - Composition a base de statines - Google Patents

Composition a base de statines Download PDF

Info

Publication number
WO2005104871A1
WO2005104871A1 PCT/EP2005/003247 EP2005003247W WO2005104871A1 WO 2005104871 A1 WO2005104871 A1 WO 2005104871A1 EP 2005003247 W EP2005003247 W EP 2005003247W WO 2005104871 A1 WO2005104871 A1 WO 2005104871A1
Authority
WO
WIPO (PCT)
Prior art keywords
statin
fat
composition
statins
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/003247
Other languages
English (en)
Other versions
WO2005104871A8 (fr
Inventor
Christiaan Michaël BEINDORFF
Willem Maarten Meijer
Henricus Otto Franciscus Molhuizen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hindustan Unilever Ltd
Unilever NV
Original Assignee
Hindustan Lever Ltd
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hindustan Lever Ltd, Unilever NV filed Critical Hindustan Lever Ltd
Priority to CA002563153A priority Critical patent/CA2563153A1/fr
Priority to BRPI0509437-2A priority patent/BRPI0509437A/pt
Priority to MXPA06012250A priority patent/MXPA06012250A/es
Priority to JP2007509906A priority patent/JP2007534708A/ja
Priority to EP05716409A priority patent/EP1740061A1/fr
Priority to US11/579,027 priority patent/US20080003266A1/en
Priority to AU2005237214A priority patent/AU2005237214B2/en
Publication of WO2005104871A1 publication Critical patent/WO2005104871A1/fr
Anticipated expiration legal-status Critical
Publication of WO2005104871A8 publication Critical patent/WO2005104871A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
    • A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Composition comprising statins
  • the present invention relates a composition comprising statin.
  • the invention further relates to the use of the composition for the preparation of a food product and to a process for the preparation of the composition.
  • Cardiovascular disease is a leading cause of morbidity and mortality, particularly in the United States and in Western European countries and is emerging in developing countries.
  • the major risk factors for heart disease are: age (65 years and older), male gender, heredity, smoking, high blood-cholesterol levels (hypercholesteremia) , high blood pressure, physical inactivity, diabetes, and obesity.
  • LDL- cholesterol Elevated low-density lipoprotein cholesterol
  • Statins are compounds that are known to have a lowering effect on levels of LDL-cholesterol in the human blood. Statins inhibit the hydroxymethylglutaryl coenzy e A (HMG-CoA) reductase, the rate-determining step in the cholesterol biosynthesis .
  • HMG-CoA hydroxymethylglutaryl coenzy e A
  • statins in food consumed by humans is associated with a lower level of LDL-cholesterol and lower risk of coronary heart disease.
  • the BMI number is calculated as a person's weight divided by that person's height. People with two or more risk factors for heart disease are at even higher risk for heart disease, when combined with a high BMI. In addition, obesity increases mortality of coronary heart disease 2-4 fold.
  • compositions comprising statins for the manufacture of food products are known.
  • WO02/64809 describes a ' process for the preparation of statins by fermentation and food products comprising one or more statins. It describes the extraction of statins from fermented soya beans with organic solvents (ethanol and acetonitril) and the use of the extract for the preparation of magarine and spreads. The drawback of this process is that the yield of the statins is rather low (0.0545 g statin/kg (ethanol extract) and 0.0978 g statin /kg (acetonitril extract) ) .
  • fermented soy material comprising statin is used for the preparation of the food products.
  • This fermented soy material comprises about 20 wt.% oil.
  • the high fat-content makes these kinds of statin containing material unsuitable for use in a low-fat diet.
  • Another object of the invention is to provide a low-fat food product comprising statins. Yet another object of the invention is to provide a process for the preparation of the composition comprising statins.
  • composition comprising statin wherein the composition is a flour comprising less than 10 wt.% of fat.
  • the present invention relates to a composition
  • a composition comprising statin characterised in that the composition is a flour comprising less than 10 wt.% of fat.
  • the flour comprises less then 5 wt.% of fat, preferably less then 1 wt.% of fat or even more preferably essentially no fat.
  • flour is defined as a fine powder obtained by grinding a starchy plant material.
  • Flour may be made from starchy plant materials including barley, buckwheat, chickpeas, lima beans, oats, peanuts, potatoes, soybeans, rice, and rye.
  • composition according to the present invention comprises statins.
  • Statins are defined as substances having the structural formula, presented in figure 1.
  • Rl and R2 can be any group.
  • Preferred statins are those which are given in figure 1.
  • statins The amounts of statins given will be expressed, in wt.% or weight parts per million (ppm) , mg/kg or mg/g, relative to the total weight of the food product, unless otherwise indicated.
  • statins given herein are the sum of the amounts of individual statins, as e.g. determined by high performance liquid chromatography (HPLC) or LC-MS, unless otherwise indicated.
  • the composition according to the present invention comprises at least 0.01 mg/g statin, more preferably 0.1 mg/g statin. Even more preferred the flour of the invention comprises at least 1 mg/g statin.
  • One embodiment of the present invention relates to the use of the composition of the present invention in the preparation a food product .
  • ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ , ⁇ , ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
  • the food product according to the invention in particular bakery products, has a low fat content.
  • the food product has less than 10 wt.% of fat, more preferably less than 5 wt.%.
  • the food product according to the invention preferably comprises statins in an amount sufficient to obtain a blood LDL-cholesterol lowering effect if the food product is used according to the common needs of the consumer.
  • statin per day The preferred intake of statin per day is herein 5-40 mg/day, more preferably 5-20 mg/day, even more preferably 8-15 mg/day. Furthermore, the intake of statin per day is preferably 1-5 mg/day, more preferably 1-2.5 mg/day.
  • the skilled person will be able to adjust the percentage of statins in the food product to obtain the desired blood cholesterol lowering effect.
  • the percentages will depend on the type of food product, since the food products are used in different serving sizes. Moreover the pattern in a food product is consumed (servings per day and distribution over days) is dependent on the food product .
  • the food product comprises 0.1-10 mg statin per serving, more preferably 1-5 mg statin per serving and even more preferably 1-2.5 mg statin- per serving.
  • compositions comprising statin wherein the composition is a flour comprising less than 10 wt.% of fat and the process comprises the steps of fermenting a substrate with a statin producing fungus, grounding the substrate, extracting the substrate, and recovering the extracted substrate, whereby the extracted substrate results in a flour comprising statin with less than 10 wt.% of fat.
  • the substrate can be grounded before or after the fermentation. Preferably the grounding is performed after the fermentation.
  • the fermented substrate may be extracted with any extracting agent provided that the extracting agent extracts the fat from the substrate.
  • the extraction of fat from fermented soybeans can be performed with a number of organic solvents: hexane, acetone, ethyl acetate and ethanol or mixtures of these.
  • the extracting agent extracts the fat from the substrate so that the extracted substrates comprises less than 10 wt.% fat, more preferably less than 5 wt.% fat, and even more preferably less than 1 wt.% fat.
  • the preferred extracting agent leaves an effective amount of statin in the substrate.
  • An effective amount of statins stands for an amount sufficient to be effective in cholesterol-lowering.
  • the extracted substrate comprises at least 0.01 mg statin per gram extracted substrate, more preferably at least 0.1 mg statin per gram extracted substrate, even more preferred at least 1 mg statin per gram extracted substrate.
  • the extracting agent is food grade. Hexane and super-critical C0 2 are preferred extracting agents .
  • the substrate may vary depending on whether it may be fermented with a statin producing fungus.
  • the substrates preferably have a high content of starchy material. Suitable substrates that may be used are soybeans, barley, buckwheat, chickpeas, lima beans, oats, peanuts, potatoes, rice, and rye.
  • soybeans may be used for a variety of products such as cookies, pastries, sweet goods, salty snacks e.g. nacho chips, prepared meals, meat replacer, pasta, pancakes, muffins, bread and bread products.
  • soybean flour comprises protein, fibers and phytoestrogen, saponins, polyphenols such as isoflavones, preferably in the non-glycosylated form. All of which have been shown to have a beneficial effect on the blood-cholesterol level and the triglycerides level in the blood.
  • Soy protein content in a food product may be measured according to the method described in Agater et al . , J. Sci. Food Agric. (1986), 37(3), 317-31.
  • Polyphenols include flavenoids, which include isoflavones.
  • the polyphenols include isoflavones, stilbenes, lignans, coumestans and resorcyclic acid lactones.
  • isoflavones are genistein, daidzein, equol, glycitein, biochanin A, coumestrol, maitaresinol, formononetin, 0- desmethylengolesin, enterolactone and enterodiol.
  • Preferred isoflavones according to the invention are genistein and daidzein and glycitein, which are present in soybeans.
  • Saponins are herein derived as ⁇ -D-glucopyranosiduronic acid derivates.
  • Examples of saponins are Soya sapogenol A,B,C,D and E, Soyasaponin I, II and III, as described in Anlagen Lexikon, B.Behr's Verlag GmbH & Co. Hamburg, Bd.2, L-Z -3, 1993, pages 550-552.
  • the food product according to the invention comprises statin and non-glycosylated isoflavone.
  • isoflavones are present substantially in the glycosylated form. Typically about 5 wt.% of the isoflavones is present in the non-glycosylated form.
  • the most important glycosylated isoflavones are genistin, daidzin and glycetin.
  • the non-glycosylated forms are respectively genistein, daidzein and glycetein. Genistein, daidzein and glycetein have been reported to have advantageous health effects, including estrogenic and antioxidant properties.
  • the glycosylated isoflavones are converted into the corresponding non-glycosylated isoflavones, which are more benificial. For instance, the amount of genistein and daidzein is increased in the fermented soy compared to the non-fermented soy.
  • the isoflavone concentration may be measured according to the HPLC method described in Franke A. . , et al. (1998): HPLC analysis of isoflavonoids and other phenolic agents from foods and human fluids; Proceed. Soc. Exp. Biol .Med; 217 (3), 274-280.
  • statins can be produced by a variety of filamentous fungi, including Monascus, Aspergillus, Penicillium, Pleurotus , Pythium, Hypo yces , Paelicilomyces , Eupenicillium, and Doratomyces .
  • the fungus is chosen from the group consisting of Monascus fungi and more preferably from the group consisting of Monascus ruber fungi.
  • red rice As a food product, rice fermented with a red Monascus fungus (red rice) has been known and used for hundreds of years in China. Red rice was used and still is used in wine making, as a food-colouring agent and as drug in traditional Chinese medicine. Most red rice available on the market contains no statins or statins in very low amounts.
  • red yeast rice available in the market does not contain significant amounts of lovastatin (FDA, Docket No. 97-0441, Final Decision) .
  • WO 99/23996 describes a composition for treating elevated serum cholesterol and/or triglycerides comprising a red rice product containing at least 0.05% lovastatin by weight.
  • Red rice powder capsules are sold as dietary supplements under the name of Cholestin by the firm Pharmanex. Pharmanex also sells a Cholestin bar containing red yeast rice (Monascus purperus went) .
  • Red rice has an intensive red colour.
  • the intensive red colour of red rice is an advantage when it is used as colouring agent, it is a disadvantage when it is used in food products.
  • Due to the intense red colour of red-rice products the foods prepared from red rice are coloured, depending on the amount of red-rice product added to the food product yellow, orange or red. The higher the amount of red rice added to the food, the more intense is the red colour of the food ' product . In some food products the red colouring is undesirable. In particular in the western world, consumers are reluctant to use products of which the colour has changed from that they are used to.
  • This numerical code used is L*a*b*.
  • Value becomes L*
  • Hue and Chroma are expressed as a* and b* respectively.
  • the L*a*b* may be measured with a UV 1601 spectofotometer of Shimatzu.
  • the food product has a Hue a* value of less than 20, preferably less than 10, most preferably less than 0.
  • Monascus strain is Monascus ruber F125 Ml-4. This strain when grown on soybeans doesn't have a red colouring.
  • the fermentation may be carried out in a manner, which can be determined by the skilled person on the basis of the methods described in WO02/064809 and WO02/063976.
  • the fermentation temperature may be important.
  • the temperature is preferably in the range of 10 to 37°C, more preferably 20 to 30°C.
  • the medium is aerated, e.g. by stirring, shaking etc.
  • Aeration may be carried out by blowing air through the fermentation medium.
  • the air is wholly or partly saturated with water vapour in case solid state fermentation is used. This avoids drying out of the fermentation medium.
  • the levels of statins will depend on the fermentation time.
  • the fermentation time is therefore dependent on the desired amount of statins.
  • Preferred fermentation time is 1-50 days, more preferably 15-40 days, most preferably 20-30 days (See WO02/064809 and WO02/063976) .
  • Fig. 1 shows a schematic representation of the structure of different statins.
  • Fig. 2 shows a schematic representation of the experimental set-up for supercritical carbon dioxide extraction.
  • lovastatins were prepared by adding an extraction mixture, containing acetonitrile, water and phosphoric acid (1:1:0.05, v/v/v) to the material in a ratio of 5:1. Usually 5 g of material was extracted with 25 ml of extraction mixture. Samples were incubated for 1 hour at room temperature and then homogenised using an Ulta-Turrax. After homogenisation the samples were incubated overnight at room temperature on a roller bench. The samples were centrifuged at 11.000 rpm for 10 minutes and the supernatants collected for HPLC analysis. The amount of lovastatin in the samples was determined by HPLC separation according to the method of Morovjan et al . J. chromatogr. A 763 (1997) 165-172.
  • the system consists of the Shimadzu SCL-10A system controller, CTO-10AS column oven, LC-10AT vp pump system, RID-10A refraction index detector, SPD-M10A diode array detector and SIL-10AD autoinjector.
  • a Waters NovaPak C18 (150x3.9 mm I.D., 4 ⁇ m) column was used operating at 25°C.
  • the eluent was an acetonitrile, water and phosphoric acid (1:1:0.05 v/v/v) solution flowing at 1.5 ml/min. Runs were performed for 15 min.
  • the detection was performed using a diode array detector from 190 nm up to 800 nm.
  • Monascus ruber F125 Ml-4 (CBS 109269) was plated on VMA-agar plates and incubated at 30 °C for 3 days.
  • Substrates like soybeans, kidney bean, mung bean, lupine seeds, walnut, maize, oat and peanuts were soaked in tap water (50°C) for 60 minutes. After soaking the substrates were rinsed with cold tap water. Subsequently the substrates were air-dried at ambient temperature for 180 minutes. The soaked and dried substrates were transferred to a shake-flask, approximately 50 g per flask. The shake flasks were sterilised by autoclaving (10 min at 120°C), inoculated with 1 ml of a fully-grown Monascus culture and incubated for an appropriate time (2-6 weeks) at 25 °C.
  • Lovastatin production is monitored and when a sufficient level has been obtained, the flasks are pasteurised by placing the flasks in an incubator at 80 °C overnight after which the end product can be harvested.
  • Table 1 gives an overview of the statin content of the end product after 3 weeks of fermentation.
  • Table 1 Amount of statin in end product after 3 weeks of fermentation
  • Example 9 Supercritical extraction of fermented soybeans For the supercritical extraction of natural solid matrices, equipment and software of Thar Designs, USA was used. The experimental set-up is schematically depicted in Fig. 2.
  • the C0 2 pump is capable of compressing liquid carbon dioxide to a pressure up to 600 bars at a constant flow-rate.
  • a polarity modifier may be mixed with the liquid carbon dioxide.
  • the carbon dioxide was heated to reach supercritical conditions before entering the extraction vessel.
  • the supercritical carbon dioxide was passed over the solid matrix for extraction.
  • the supercritical carbon dioxide was expanded over an automated backpressure regulator.
  • the backpressure regulator was coupled to a feedback control unit to control the pressure in the system.'
  • the carbon dioxide was separated from the extracted material (liquid/solid) in a cyclone separation system. The carbon dioxide left the cyclone at the top, while the extracted material remained in the cyclone.
  • the liquids extracted from the solid matrix were recovered during the experiment by opening the valve at the bottom of the cyclone.
  • the carbon dioxide gas was further expanded over a further backpressure regulator, which was operated manually.
  • a gas clock downstream of the backpressure regulator registers how much gas has been put through the system, before the carbon dioxide leaves the system at ambient pressure.
  • the process equipment is designed to operate at the following conditions:
  • the fermented soybeans were ground prior to extraction in a water-cooled universal mill (type M20, IKA, Germany) until a fine powder was obtained.
  • the amount of sample used for extraction was 100 gram of ground fermented soybeans.
  • the fermented and ground soybeans were put in the extraction vessel and the remaining volume was filled with small glass beads (2 mm diameter) .
  • the flow rate of liquid carbondioxide was 20 g*min _1 .
  • the extracted oil was collected.
  • the total extraction time was 2 hours .
  • the extraction vessel was opened and a dry free-flowing soybean flour powder was obtained.
  • the added glass beads were removed by sieving.
  • An aliquot of the soybean flour was analysed for the amount of Lovastatin. Both in the starting material as well as in the extracted material the amount protein, moisture fat and ash were determined.
  • Table 3 Composition of grounded fermented soybeans before and after supercritical fluid extraction.
  • Example 10 Soxhlet extraction with hexane of fermented soybeans
  • Example A Soxhlet extraction with ethanol of fermented soybeans
  • soybean fat is efficiently removed resulting in a defatted soy flour (fat content ⁇ 5 wt.% ).
  • Lovastatin present in the defatted soy flour.
  • Ethanol is less suitable as it does not remove the fat as efficient as hexane or supercritical fluid and also leaves less statin in the extracted flour.
  • Example 11 Preparation of low-fat oat-pancakes with banana and orange
  • Preparation In a large bowl, combine the rolled oats, unbleached flour, soy flour and baking powder. Add the soymilk, and blend with a few swift strokes. Fold in the banana and orange slices.
  • the pancakes can be served with e.g. maple 'syrup, apple sauce or a fruit spread.
  • Preparation Mix the ingredients thoroughly in a dough mixer. Proof the dough. Allow the dough to rise for 30-60 min at a temperature of 20°C. Put the risen dough in a bread tin. Bake the bread at 190°C for 30-60 min.
  • Example 13 Preparation of low-fat orange-banana muffins formulation:
  • Preparation Combine dry ingredients in bowl. Mix orange juice, vanilla, banana, honey and half of the egg whites in a bowl on low speed until blended. Add dry ingredients and mix for a few seconds, just until moistened and no flour can be detected. Beat the remaining egg whites and stir into the above mixture. Add raisins. Fill paper cupcake liners in muffin tins and fill cups to within 0.3 inch of top. Bake at 180°C for 10-24 min until you can touch the muffin lightly on top and the imprint does not remain. Serving size: 75 g, amount statins per serving: 6.5 mg. The flour with statins may be party replaced by whole wheat flour and/or all purpose flour, this allows for easy variation of the statin content.
  • Example 14 Preparation of low-fat pasta
  • the ingredients were mixed to form the pasta.
  • the pasta was then formed with a pasta maker into long noodle-like threads.
  • the pasta was cooked for 5 minutes.
  • the consumption of 80 g pasta would result in an estimated blood cholesterol lowering of 5%.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Agronomy & Crop Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Noodles (AREA)
  • Medicinal Preparation (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)

Abstract

L'invention concerne une composition à base de statines qui se présente sous forme de farine comprenant moins de 10 % en poids de graisse, ainsi que son utilisation dans la préparation d'un produit alimentaire. Le procédé de préparation de la composition à base de statines comprend les étapes consistant à faire fermenter un substrat avec un champignon producteur de statines et à procéder à l'extraction du substrat.
PCT/EP2005/003247 2004-04-28 2005-03-23 Composition a base de statines Ceased WO2005104871A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002563153A CA2563153A1 (fr) 2004-04-28 2005-03-23 Composition a base de statines
BRPI0509437-2A BRPI0509437A (pt) 2004-04-28 2005-03-23 composição que compreende estatina, uso de uma composição, produto alimentìcio e processo para a preparação de uma composição
MXPA06012250A MXPA06012250A (es) 2004-04-28 2005-03-23 Composicion que comprende estatinas.
JP2007509906A JP2007534708A (ja) 2004-04-28 2005-03-23 スタチンを含有する組成物
EP05716409A EP1740061A1 (fr) 2004-04-28 2005-03-23 Composition a base de statines
US11/579,027 US20080003266A1 (en) 2004-04-28 2005-03-23 Composition Comprising Statins
AU2005237214A AU2005237214B2 (en) 2004-04-28 2005-03-23 Composition comprising statins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04076293 2004-04-28
EP04076293.2 2004-04-28
EP04077219 2004-08-03
EP04077219.6 2004-08-03

Publications (2)

Publication Number Publication Date
WO2005104871A1 true WO2005104871A1 (fr) 2005-11-10
WO2005104871A8 WO2005104871A8 (fr) 2007-04-19

Family

ID=34962306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003247 Ceased WO2005104871A1 (fr) 2004-04-28 2005-03-23 Composition a base de statines

Country Status (10)

Country Link
US (1) US20080003266A1 (fr)
EP (1) EP1740061A1 (fr)
JP (1) JP2007534708A (fr)
AU (1) AU2005237214B2 (fr)
BR (1) BRPI0509437A (fr)
CA (1) CA2563153A1 (fr)
MX (1) MXPA06012250A (fr)
RU (1) RU2006141847A (fr)
TW (1) TW200539814A (fr)
WO (1) WO2005104871A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162441A1 (it) * 2016-04-08 2017-10-08 Massimo Farinon Pasta alimentare
CN106578907A (zh) * 2016-12-15 2017-04-26 张家口市农业科学院 一种全燕麦粉馒头及其制作方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712130A (en) * 1993-06-08 1998-01-27 Krka Tovarna Zdravil, P.O Process for the isolation of lovastatin
WO1999023996A2 (fr) * 1997-11-06 1999-05-20 Peking University Compositions contenant des produits fermentes a base de riz rouge et procedes associes
WO2002063976A1 (fr) * 2001-02-09 2002-08-22 Unilever N.V. Produit alimentaire comprenant une proteine de soja et des statines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3734901A (en) * 1970-09-28 1973-05-22 Staley Mfg Co A E Defatted soybean fractionation by solvent extraction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712130A (en) * 1993-06-08 1998-01-27 Krka Tovarna Zdravil, P.O Process for the isolation of lovastatin
WO1999023996A2 (fr) * 1997-11-06 1999-05-20 Peking University Compositions contenant des produits fermentes a base de riz rouge et procedes associes
WO2002063976A1 (fr) * 2001-02-09 2002-08-22 Unilever N.V. Produit alimentaire comprenant une proteine de soja et des statines
WO2002064809A2 (fr) * 2001-02-09 2002-08-22 Unilever N.V. Methode de preparation d'une ou plusieurs statines par fermentation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ECKARD, STRODE, TAYLOR: "Investigation of Primary and Secondary Modifiers fror the Subcritical Extraction of Lovastatin from MEVACOR Tablets with Carbon DIoxide", JOURNAL OF CHROMATOGRAPHIC SCIENCE, vol. 36, no. 3, March 1998 (1998-03-01), pages 139 - 145, XP008034045 *
MANZONI M ET AL: "PRODUCTION AND PURIFICATION OF STATINS FROM ASPERGILLUS TERREUS STRAINS", BIOTECHNOLOGY TECHNIQUES, CHAPMAN & HALL, vol. 12, no. 7, July 1998 (1998-07-01), pages 529 - 532, XP000921032, ISSN: 0951-208X *
MANZONI M ET AL: "PRODUCTION OF STATINS BY FILAMENTOUS FUNGI", BIOTECHNOLOGY LETTERS, KEW, SURREY, GB, vol. 21, 1999, pages 253 - 257, XP000864633, ISSN: 0141-5492 *

Also Published As

Publication number Publication date
RU2006141847A (ru) 2008-06-10
EP1740061A1 (fr) 2007-01-10
AU2005237214B2 (en) 2008-05-22
WO2005104871A8 (fr) 2007-04-19
TW200539814A (en) 2005-12-16
JP2007534708A (ja) 2007-11-29
BRPI0509437A (pt) 2007-09-04
US20080003266A1 (en) 2008-01-03
CA2563153A1 (fr) 2005-11-10
AU2005237214A1 (en) 2005-11-10
MXPA06012250A (es) 2006-12-15

Similar Documents

Publication Publication Date Title
Valcárcel-Yamani et al. Applications of quinoa (Chenopodium quinoa Willd.) and amaranth (Amaranthus spp.) and their influence in the nutritional value of cereal based foods.
US20030108657A1 (en) Process for the preparation of one or more statins by frementation
Fletcher Food sources of phyto-oestrogens and their precursors in Europe
JP2022531891A (ja) 菌糸化された増量組成物の製造方法
Mervat et al. Effect of fortification by full fat and defatted flaxseed flour sensory properties of wheat bread and lipid profile laste
Di Cairano et al. Functional cereal-based bakery products, breakfast cereals, and pasta products
CN1946304A (zh) 包含他汀的组合物
Lopez-Martinez et al. Amaranth seeds: A promising functional ingredient for gastronomy–A review
Kutlu et al. Teff: Its applicability in various food uses and potential as a key component in gluten-free food formulations—An overview of existing literature research
Komolka et al. Sensory qualities of pastry products enriched with dietary fiber and polyphenolic substances
AU2005237214B2 (en) Composition comprising statins
JPWO2018012262A1 (ja) メタボリックシンドローム抑制剤
JP2006075003A (ja) 大豆紅麹およびそれを含む飲食物
Adebiyi Metabolic Profile, Health Promoting Properties and Safety of Dawadawa (A Fermented Condiment) from Bambara Groundnut (Vigna Subterranea)
Konsam A comparative study on the nutritional characterization of coagulant assisted tofu
Davy et al. 15 Soybean Processing By-Products and Potential
Gandhi FUNCTIONALITY OF PROCESSED LENTILS (Lens culinaris) IN FOOD PRODUCTS
Bunkar PROCESS OPTIMIZATION AND SHELF LIFE EVALUATION OF BLACK RICE BASED INSTANT DRY IDLI MIX
Yadav et al. Processing effects on functional components in cereals and grains
Cachaper The Effect of Antioxidants on Flaxseed Stability in Yeast Bread
Davis The effect of soy flour as a natural antioxidant on flaxseed in yeast bread
MATSUO Taste, Antioxidative Activity and Antimutagenicity of Low-Salt Miso Made from Soybeans and Okara Fermented with Neurospora intermedia
Abd El-Rahman et al. Quality and Nutritional Characteristics of Sesame Nuts Fortified with Black Cumin and Oat Seeds
Zenere Physicochemical and sensory properties of a chip-type snack food based on defatted peanut and soy flour

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005716409

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2563153

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200608311

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2007509906

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005237214

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/012250

Country of ref document: MX

Ref document number: 200580012633.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11579027

Country of ref document: US

Ref document number: 1261/MUMNP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005237214

Country of ref document: AU

Date of ref document: 20050323

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005237214

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006141847

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005716409

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0509437

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11579027

Country of ref document: US